Bayesian Model Prediction for Breast Cancer Survival: A Retrospective Analysis.

Eur J Breast Health

Adult Health Nursing Clinical Nursing Department, School of Nursing, University of Jordan, Amman, Jordan.

Published: June 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Over the recent years, machine learning (ML) models have been increasingly used in predicting breast cancer survival because of improvements in ML algorithms. However, cancer researchers still face a significant challenge in accurately predicting breast cancer patients' survival rates. The purpose was to predict breast cancer survival using a Bayesian network.

Materials And Methods: This retrospective study included 2,995 patients diagnosed with breast cancer and subsequently hospitalized between January 1, 2012, and December 30, 2024. SPSS Modeler version 18.0 was used to build prediction models. The data were randomly split into a training set (2,097 cases, 70%) and a test set (898 cases, 30%) for developing the Bayesian network model and predicting the overall survival of patients diagnosed with breast cancer. The model included demographic variables (age, marital status, and governorate), laboratory/clinical variables (hemoglobin level, white blood cell count, presence of hypertension, and diabetes mellitus) and the outcome variable, patient survival status (binary value: survived/died). The discriminative ability of models was evaluated by accuracy and the area under the curve (AUC) in terms of superior predictive performance for breast cancer outcomes.

Results: The Bayesian model exhibited the best discriminatory performance among the nine models, with an AUC of 0.859 and the highest accuracy of 96.661%. In the context of feature importance, white blood cell value at the time of diagnosis was the most important feature for predicting the survival of breast cancer. Patients who had below-normal hemoglobin and above-normal white blood count values had a higher death probability than patients who had normal white blood count and hemoglobin values. The presence of hypertension and diabetes mellitus in patients with breast cancer led to a reduced survival probability.

Conclusion: The Bayesian model outperformed the other models in predicting the survival probability of breast cancer. Routine laboratory testing and demographic data can be included in a ML model to predict breast cancer survival. Accurate prediction of breast cancer survival is vital for clinical decision-making.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180110PMC
http://dx.doi.org/10.4274/ejbh.galenos.2025.2025-2-14DOI Listing

Publication Analysis

Top Keywords

breast cancer
48
cancer survival
20
white blood
16
cancer
13
bayesian model
12
breast
12
predicting survival
12
survival
11
prediction breast
8
predicting breast
8

Similar Publications

Background: Breast cancer treatment, particularly during the perioperative period, is often accompanied by significant psychological distress, including anxiety and uncertainty. Mobile health (mHealth) interventions have emerged as promising tools to provide timely psychosocial support through convenient, flexible, and personalized platforms. While research has explored the use of mHealth in breast cancer prevention, care management, and survivorship, few studies have examined patients' experiences with mobile interventions during the perioperative phase of breast cancer treatment.

View Article and Find Full Text PDF

Oligomeric proanthocyanidins (OPCs), condensed tannins found plentiful in grape seeds and berries, have higher bioavailability and therapeutic benefits due to their low degree of polymerization. Recent evidence places OPCs as effective modulators of cancer stem cell (CSC) plasticity and tumor growth. Mechanistically, OPCs orchestrate multi-pathway inhibition by destabilizing Wnt/β-catenin, Notch, PI3K/Akt/mTOR, JAK/STAT3, and Hedgehog pathways, triggering β-catenin degradation, silencing stemness regulators (OCT4, NANOG, SOX2), and stimulating tumor-suppressive microRNAs (miR-200, miR-34a).

View Article and Find Full Text PDF